BioCryst Pharmaceuticals (NASDAQ: BCRX)
BioCryst Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioCryst Pharmaceuticals Company Info
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
News & Analysis
Why BioCryst Pharmaceuticals Stock Is Soaring Today
The biotech's Q1 earnings report contained a number of positives.
Why Shares of BioCryst Pharmaceuticals Jumped Today
A day after the stock plummeted, it bounced back.
Why BioCryst Pharmaceuticals Stock Is Sinking Today
Investors didn't like the drugmaker's Q4 update.
Got $3,000? Here Are 2 Stocks That Will Make You Richer
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.
2 Biotech Stocks You'll Regret Not Buying on the Dip
BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.
Why BioCryst Pharmaceuticals Topped the Market Today
The company receives some good news from a top regulator.
Why BioCryst Stock Lost Nearly 4% of Its Value Today
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
Valuation
Earnings Transcripts
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023.
BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2023.
BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2023.
BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.